ISDA

Entry Detail

PDB ID:

9MZZ

Keywords:

TRANSFERASE/INHIBITOR

Title:

Crystal structure of RIPK1 with compound 36

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2025-01-23

Release Date:

2025-05-28

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.68 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Receptor-interacting serine/threonine-protein kinase 1
Chain IDs:A, B
Chain Length:288
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q13546 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

A1BU5

IOD

Primary Citation

The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1.

Chen, J.L, Methot, J.L, Mitcheltree, M.J, Musacchio, A, Corcoran, E.B, Feng, G, Lammens, A, Maskos, K, Palte, R.L, Rickard, M.M, Otte, K.M, Mansueto, M.S, Venkat, S, Sondey, C, Thomsen, M, Lesburg, C.A, Fradera, X, Fell, M.J, DiMauro, E.F, Siliphaivanh, P.Show

Acs Med.Chem.Lett. 16 811 818 (2025)

PMID: 40365380 DOI: 10.1021/acsmedchemlett.5c00063

Abstact

Receptor-interacting protein kinase 1 (RIPK1) plays an essential role in necroptosis, a form of inflammatory, caspase-independent, programmed cell death. Allosteric inhibitors of RIPK1 have been shown to block necroptotic cell death and thus may offer potential therapeutic opportunities across a range of infectious, autoimmune, and neurodegenerative diseases. We report the structure-informed discovery of a novel series of bridged benzoazepine amides as part of our efforts to develop a CNS-penetrant small-molecule inhibitor of RIPK1 with a low projected oral human dose.

Legend

Protein

Chemical

Disease

Primary Citation of related structures